Market Research Logo

Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets

Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets

The global market for erythropoietin stimulating agents (ESAs) will grow from nearly $7.2 billion in 2015 to nearly $7.3 billion by 2020 with a compound annual growth rate (CAGR) of 0.2% for the period 2015-2020.
This report provides:

An overview of the global markets and therapeutic applications for erythropoietin stimulating agents (ESAs).
Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
Coverage of the market in value terms broken down by major types of erythropoietin, by major regions, and by applications.
Coverage of applications including cancer therapy, chronic kidney disease (CKD) therapy, HIV therapy, and anemia therapy.
Major trends and challenges affecting the market and the supplier landscape.
A look at industrial developments and the advent of biosimilars impacting the market.
Analysis of the risks associated with the market for abusive uses of ESAa and their adverse effects.
Profiles of major players in the industry.


SCOPE OF REPORT

The scope of this report is broad and covers erythropoietin drug used globally in various types of applications. The market is broken down in terms of the various types of erythropoietin drug by region and by applications. Revenue forecasts from 2015 to 2020 are given for erythropoietin drug, with its applications and regional markets.

The report also includes a discussion of the major players in each of the regional markets for erythropoietin drug. It explains the major market drivers of the global erythropoietin drug industry, the current trends within the industry, major industry challenges and the regional dynamics of the global erythropoietin drug market. The report concludes with a special focus on the supplier landscape. It includes detailed profiles of the major vendors in the erythropoietin drug industry globally.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
INFORMATION SOURCES
RESEARCH METHODOLOGY
ANALYSTS' CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, 2014-2020 ($ MILLIONS)
CHAPTER 3 OVERVIEW
DEFINITION
ERYTHROPOIETIN AS A DRUG
DEVELOPMENTAL STAGES OF ERYTHROPOIETIN
APPLICATIONS OF ERYTHROPOIETIN
SIDE EFFECTS OF ERYTHROPOIETIN
CARDIOVASCULAR
HEMATOLOGIC
CENTRAL NERVOUS SYSTEM
PSYCHIATRIC
ONCOLOGIC
GASTROINTESTINAL
DERMATOLOGIC
PROS AND CONS OF MANUFACTURING METHODS:
PROS
CONS
CHAPTER 4 R&D DRUG PIPELINE
TABLE 1 MAJOR EPO R &D DRUG PIPELINE BY TRIAL PHASE
CHAPTER 5 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUG
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY CATEGORY
TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH 2020 ($ MILLIONS)
FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY TYPE
TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE
TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE
TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION
TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUG
MARKET BY REGION
TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
REGION
TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION
TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY REGION
TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY REGION
TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DARBEPOETIN-ALFA
DRUGS BY REGION
TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETINBIOLOGIC DRUGS BY REGION
TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS
BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION
TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION
TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION
TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY APPLICATION
TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY APPLICATION
TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR DARBEPOETIN-ALFA BY APPLICATION
TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPPOIETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION
TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC
DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY REGION
TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY APPLICATION
TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY REGION
TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 24 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY APPLICATION
TABLE 26 GLOBAL MARKET FOR PROCRIT DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 25 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR EPREX DRUGS BY REGION
TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR EPREX DRUGS BY APPLICATION
TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY REGION
TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY APPLICATION
TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY PPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY REGION
TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY APPLICATION
TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR MIRCERA DRUGS BY REGION
TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND 2020 (%)
GLOBAL MARKET FORECAST FOR MIRCERA BY APPLICATION
TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY PPLICATION,
2015 AND 2020 (%)
CHAPTER 6 DRIVERS AND CHALLENGES
INCREASING CASES OF CHRONIC KIDNEY DISEASE
DIABETES
FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013 AND 2035 (MILLIONS)
FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP TEN COUNTRIES, 2013 (MILLIONS)
FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY IABETES,
BY TOP TEN COUNTRIES, 2035 (MILLIONS)
FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013 (MILLIONS)
HYPERTENSION
FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 EARS BY REGION, 2008 AND 2014
TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 000-2025 (MILLIONS)
TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 012
(MILLIONS)
TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS)
TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012 (MILLIONS)
INCREASING PREVALENCE OF CANCER
FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%)
FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE, 2008-2012 (%)
FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012 (%)
FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE,
2012 (%)
FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS
RISK OF THROMBOSIS AND PURE RED CELL APLASIA (PRCA)
CARDIOVASCULAR PROBLEMS
THROMBOSIS IN CANCER PATIENTS
INCREASED TUMOR PROGRESSION
ZIVODUINE TREATED HIV INFECTED PATIENTS
PURE RED CELL APLASIA
INCREASING GENERIC COMPETITION
SYNTHETIC ERYTHROPOIETIN
TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY
CHAPTER 7 VENDOR LANDSCAPE AND COMPANY PROFILES
TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY MANUFACTURER, 2014 (%/$ MILLIONS)
3SBIO INC.
TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
AMEGA BIOTECH
AMGEN INC.
TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE
TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS
TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 ($ MILLIONS)
TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 ($ MILLIONS)
TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%)
FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%)
BIOCON
FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%)
TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%)
BIOSIDUS
BLAUSIEGEL
CELON LABS
CENTER OF MOLECULAR IMMUNOLOGY
CHALVER LABORATORIES
CJ HEALTHCARE
CLARIS LIFESCIENCES
TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
DR. REDDY'S LABORATORIES.
FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%)
TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
EMCURE PHARMACEUTICALS
HINDUSTAN ANTIBIOTICS
HOSPIRA INC.
TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 50 HOSPIRA'S SALES BY REGION, 2014
FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%)
INTAS BIOPHARMACEUTICAL LTD
TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%)
FIGURE 52 INTAS' SALES BY REGION, 2014 (%)
JCR PHARMACEUTICALS CO. LTD.
TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH 2015 ($ MILLIONS)
FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%)
JOHNSON & JOHNSON
TABLE 53 JOHNSON & JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 ($ MILLIONS)
FIGURE 54 JOHNSON & JOHNSON'S SALES BY SEGMENT, 2014 (%)
TABLE 54 JOHNSON & JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
LANDSTEINER SCIENTIFIC S.A. DE C.V.
LA RENON HEALTHCARE
LG LIFE SCIENCES
TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
LUPIN LTD.
TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%)
MEDICE DRUG PUTTER GMBH & CO. KG
NOVARTIS INTERNATIONAL AG
TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%)
FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%)
PANACEA BIOTEC
TABLE 58 COMPOSITIONS OF ERYTHROPOIETIN MANUFACTURED BY PANACEA
TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%)
PROBIOMED
RELIANCE LIFE SCIENCES
ROCHE
TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 ($ MILLIONS)
TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 ($ MILLIONS)
TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 ($ MILLIONS)
TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
RPG LIFE SCIENCES
TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 %)
FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%)
SERUM INSTITUTE OF INDIA
SHANGHAI CHEMO WANBANG BIOPHARMA CO. LTD.
SHANTHA BIOTECHNICS
STADA ARZNEIMITTEL AG
TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%)
FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 ($ ILLIONS)
SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%)
FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%)
FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
FIGURE 66 TEVA'S SALES BY REGION, 2014 (%)
VHB LIFE SCIENCES LTD.
WOCKHARDT LIMITED
FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%)
TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
ZUVENTUS HEALTH CARE
ZYDUS CADILA HEALTHCARE
TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report